NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study

Movement Disorders

Volumn 30, Issue 12, 2015, Pages 1681-1687

  O'Brien, Christopher F ^a   Jimenez, Roland ^a   Hauser, Robert A ^b   Factor, Stewart A ^c   Burke, Joshua ^a   Mandri, Daniel ^d   Castro Gayol, Julio C ^e  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c EMORY UNIVERSITY   (United States)

^d Biscayne Bay Institute   (United States)

^e International University in Miami   (United States)

Author keywords

Antipsychotic drugs; Randomized controlled trial; Tardive dyskinesia; Vesicular monoamine transporter (VMAT2)

Indexed keywords

PLACEBO; VALBENAZINE; TETRABENAZINE; VALINE; VESICULAR AMINE TRANSPORTER;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TARDIVE DYSKINESIA; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; MOVEMENT DISORDERS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TETRABENAZINE; TREATMENT OUTCOME; VALINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84944514959     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26330     Document Type: Article

References (22)

1. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-156.
2. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463-474.
3. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3.
4. Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987;2:125-129.
5. Guy W, ed. ECDEU Assessment Manual of Psychopharmacology. National Institute of Mental Health (U.S.), Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
6. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69:546-554.
7. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999;56:836-841.
8. Aia PG, Revuelta GJ, Cloud LJ, Factor SA. Tardive dyskinesia. Current Treatment Options in Neurology 2011;13:231-241.
9. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81:463-469.
10. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609.
11. Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int 2014;73:89-97.
12. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
14. Jeste DV, Palmer BW, Appelbaum PS, et al. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 2007;64:966-974.
15. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatry Scand Suppl 1970;212:11-19.
17. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
19. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
20. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
22. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease. Neurology 2006;66:366-372.